DOI: 10.1097/01.COT.0000316108.81591.e1
,
Issn Print: 0276-2234
Publication Date: 2006/08/10
Facebook
Twitter
LinkedIn
Email
 |
Checking for direct PDF access through Ovid | |
Excerpt
“Patients diagnosed with advanced gastric cancer have a poor prognosis and treatment can be very cumbersome,” Howard A. Burris III, MD, Director of Drug Development at the Sarah Cannon Research Institute in Nashville, said in a news release from capecitabine's manufacturer.
“With the combination of Xeloda and cisplatin, we're seeing the promise of a treatment option that is as effective as standard therapy, well-tolerated, and has the added benefit of reducing the amount of time needed for treatment at a clinic or hospital, which may help some patients continue to spend valuable time with family and friends.”
The international, randomized, non-inferiority study was conducted by Professor Y. K. Kang of the Asan Medical Center in Seoul and included 316 patients from 46 centers in 13 countries who were previously untreated and had advanced or metastatic gastric cancer.
Patients receiving XP lived at least as long without progression as those treated with FP (median progression-free survival was 5.6 vs 5.0 months), and also lived at least as long overall (10.5 vs 9.3 months).
The XP overall response rate was superior to standard therapy (41% vs. 29%), and XP reduced the amount of time patients needed to spend in the clinic by 80% (1 day vs 5 days every three weeks).
Both study arms had acceptable and similar safety profiles, with no unexpected toxicities, Professor Kang and his colleagues reported. XP was as least as well tolerated as FP.
